Literature DB >> 11120787

CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme.

H P Hansen1, S Dietrich, T Kisseleva, T Mokros, R Mentlein, H H Lange, G Murphy, H Lemke.   

Abstract

CD30 is a costimulatory receptor on activated lymphocytes and a number of human lymphoma cells. Specific ligation of membrane-bound CD30 or cellular stimulation by PMA results in a metalloproteinase-mediated down-regulation of CD30 and release of its soluble ectodomain (sCD30). In this report, it is demonstrated that PMA-induced CD30 cleavage from Karpas 299 cells was mediated by a membrane-anchored metalloproteinase which was active on intact cells following 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate extraction of membrane preparations. Moreover, CD30 shedding was blocked by the synthetic hydroxamic acid-based metalloproteinase inhibitor BB-2116 (IC(50), 230 nM) and the natural tissue inhibitor of metalloproteinases (TIMP)-3 (IC(50), 30 nM), but not by the matrix metalloproteinase inhibitors TIMP-1 and TIMP-2. This inhibition profile is similar to that of the TNF-alpha- converting enzyme (TACE) and, indeed, mRNA transcripts of the membrane-bound metalloproteinase-disintegrin TACE could be detected in Karpas 299 cells. The ectodomain of TACE was expressed in bacteria as a GST fusion protein (GST-TACE) which cleaved CD30 from the surface of Karpas 299 cells and concomitantly increased the level of sCD30 in the cell supernatants. Hence, TACE does not only control the release of TNF-alpha, but also that of sCD30.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120787     DOI: 10.4049/jimmunol.165.12.6703

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Molecular and cellular mechanisms of ectodomain shedding.

Authors:  Kazutaka Hayashida; Allison H Bartlett; Ye Chen; Pyong Woo Park
Journal:  Anat Rec (Hoboken)       Date:  2010-06       Impact factor: 2.064

3.  Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Authors:  Satoshi Nagata; Tomoko Ise; Masanori Onda; Kazuyasu Nakamura; Mitchell Ho; Andrew Raubitschek; Ira H Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

4.  Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients.

Authors:  Cécile Contin; Vincent Pitard; Yahsou Delmas; Nadège Pelletier; Thierry Defrance; Jean-François Moreau; Pierre Merville; Julie Déchanet-Merville
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

Review 5.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

6.  Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.

Authors:  A Cerutti; E C Kim; S Shah; E J Schattner; H Zan; A Schaffer; P Casali
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

7.  Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Jimmy Esoinoza; Francesca Gotsch; Samuel Edwin; Tinnakorn Chaiworapongsa; Pooja Mittal; Eleazar Soto; Offer Erez; Shali Mazaki-Tovi; Nandor Gabor Than; Lara A Friel; Bo Hyun Yoon; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-11

8.  Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Sonia S Hassan; Francesca Gotsch; Samuel Edwin; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Shali Mazaki-Tovi; Eleazar Soto; Nandor Gabor Than; Lara A Friel; Bo Hyun Yoon; Jimmy Espinoza
Journal:  J Matern Fetal Neonatal Med       Date:  2007-12

Review 9.  ADAM function in embryogenesis.

Authors:  Dominique Alfandari; Catherine McCusker; Hélène Cousin
Journal:  Semin Cell Dev Biol       Date:  2008-09-30       Impact factor: 7.727

10.  Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin-1.

Authors:  Ulla Schwertassek; Yves Balmer; Marcus Gutscher; Lars Weingarten; Marc Preuss; Johanna Engelhard; Monique Winkler; Tobias P Dick
Journal:  EMBO J       Date:  2007-06-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.